Animals ; Chronic Disease ; Heart Failure ; drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; adverse effects ; therapeutic use

Cholesterol ; metabolism ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Metabolic Diseases ; prevention & control ; Phytotherapy

Diagnostic Errors ; Humans ; Pneumoconiosis ; diagnosis ; Scleroderma, Systemic ; diagnosis

Bacteremia ; microbiology ; Female ; Humans ; Infant ; Pseudomonas Infections ; pathology ; Pseudomonas aeruginosa

0.4,P0.05)with HHS.[Conclusion]The result of this study suggest that HHS can not capture additional important quality of life domains except for physical function and pain relief that are influenced by THA.So it's necessary to combine HHS and a quality of life survey such as SF-36 to allow a more global assessment of THA.

To obtain the criterion of Laser induced Autofluorescence (LIF) spectroscopy in the differentiation of normal lung tissue and lung cancer and study the feasibility of LIF spectroscopy in the diagnosis of lung cancer, the LIF spectra of normal lung and lung cancer in 42 surgical specimens have been measured with a detecting system which consists of an YAG laser(wavelength 355nm) and an optical multichannel analyzer(OMA). Spectroscopic differences between normal lung and cancerous tissues have been found which could be used as a criterion to distinguish from them . The pathological examinations were done to compare with the criterion. The results showed:① The location of the principal spectral peaks of the normal lung tissue (470.8?6.3)nm and lung cancer ( 463.7 ?4.8)nm are different( P

Objective To evaluate the efficacy of pegylated interferon α-2a and entecavir (ETV) combination therapy for patients with HBeAg positive chronic hepatitis B (CHB).Methods Fifty eight HBeAg positive CHB patients were assigned to two groups:29 patients received ETV 0.5 mg daily for 72 weeks (ETV group) and 29 patients received ETV and pegylated interferon α-2a 180 μg weekly for 48 weeks followed by ETV alone for 24 weeks (combination group).Serum samples were collected from all patients every 12 weeks for assessment of biochemical,virological and serological responses to treatment.Results Fifty four patients completed the 72-week study,including 28 in ETV group and 26 in combination group.There were no significant differences in week 24,week 48 and week 72 of ALT normalization [72％ (21/29)vs.93％ (27/29),x2 =2.104;90％ (26/29) vs.97％ (28/29),x2 =0.269;90％ (26/29) vs.97％ (28/29),x2 =0.269],HBV DNA undetectable rate [31％ (8/26) vs.46％ (13/28),x2 =1.391;62％ (16/26) vs.57％ (16/28),x2 =0.108;77％ (20/26) vs.75％ (21/28),x2 =0.027],HBeAg loss rate[12％(3/26) vs.25％ (7/28),x2 =0.850;31％ (8/26) vs.32％ (9/28),x2 =0.012;46％ (12/26) vs.36％(10/28),x2 =0.609] and HBsAg levels (log10 IU/ml) (3.63 ± 0.45 vs.3.36 ± 1.18,t =-1.066;3.45 ±0.43 vs.3.23 ± 1.15,t =-0.915;3.36 ± 0.58 vs.2.88 ± 1.28,t =-1.762) between two regimens (all P ＞ 0.05).Among 58 patients,15 were HBeAg and anti-HBe double-positive (26％)and 43 were HBeAg mono-positive patients.The baseline HBV DNA level [(5.07 ± 1.50) vs.(6.40 ± 1.47) log10 IU/ml,t =2.858,P ＜ 0.05] and HBeAg titer [14 (4-45) vs.732 (296-1 012) S/CO,Z =-5.031,P =0.05] in double-positive patients were lower than those in mono-positive patients.The HBV DNA undetectable rate of double-positive patients was significantly higher than that of mono-positive patients in 24 weeks [10/15 vs.26％ (10/39),x2 =7.819,P ＜0.05] and 72 weeks [15/15 vs.69％ (27/39),x2 =4.287,P =0.05].The HBeAg loss rate of double-positive patients was higher than that of mono-positive patients in 12 weeks [6/15 vs.10％ (4/39),x2 =4.533,P =0.05] and 48 weeks [9/15 vs.26％ (10/39),x2 =5.608,P =0.018].This tendency was more significant in the combination therapy group,but the difference was not statistically significant.(5/6 vs.4/9,P =0.065).Conclusions Compared with Entecavir monotherapy,entecavir combined with interferon may not improve the therapeutic effect in HBeAg positive chronic hepatitis B patients.However,the therapeutic response of HBeAg/anti-HBe double-positive patients may better than that of HBeAg mono-positive patients.

Objective To explore the value of blood lipid and CA125 in identification diagnosis between lung cancer and pulmo‐nary tuberculosis .Methods The blood lipid and serum CA125 levels in 131 patients with lung cancer( Ⅰ - Ⅳ stage) ,53 patients with pulmonary tuberculosis and 60 normal controls were determined by biochemstry ,immunoturbidimetry and electrochemilumi‐nescence immunoassay and was done compared study .Results The serum TC and HDL‐C level in 131 patients with lung cancer were decreased with severity and were lower than in those of in 53 patients with pulmonary tuberculosis(TC :P< 0 .05 ,< 0 .05 ,<0 .01 and < 0 .001 respectively ;HDL‐C :P< 0 .05 ,< 0 .05 ,< 0 .01 and < 0 .01 respectively) .The serum LDL‐C level was no differ‐ences between lung cancer( Ⅰ - Ⅲ stage) and in 53 patients with pulmonary tuberculosis(P> 0 .05) only the lung cancer( Ⅳ stage) was a little increased(P< 0 .05) .The serum TG and ApoB/ApoA1 ratio levels in 131 patients with lung cancer( Ⅰ - Ⅳ stage) were increased with severity and were significantly higher than in those of 53 patients with pulmonary tuberculosis (TG :P < 0 .05 ,< 0 .05 ,< 0 .01 and < 0 .01 respectively ;ApoB/ApoA1 :P< 0 .05 ,< 0 .05 ,< 0 .01 and < 0 .01 respectively) .The level of CA125 in 131 patients with lung cancer was significantly higher than in those 53 patients with pulmonary tuberculosis(P< 0 .001) .Conclusion The serum TC and HDL‐C ,TG ,ApoB/ApoA1 ratio and CA125 levels may be the indexs of identification diagnosis between lung cancer and pulmonary tuberculosis .

Chemokine CXCL9/Mig (monokine induced by IFN-?) belongs to the subfamily of chemotactic cytokines known as CXC-chemokines. In vivo CXCL9 is mainly induced by IFN-? in macrophages and primary glial cells. In vitro, CXCL9 can be secreted by cells such as macrophages, microvascular endothelial cells and neutrophils, in response to the synergy of IFN-? and TLR(toll-like receptor) ligands. CXCL9 is a chemoattractant for activated T lymphocytes, tumor-infiltrating T-lymphocytes, but not for neutrophils or monocytes. The receptor specific for CXCL9 is CXCR3, a G protein-coupled protein which has seven transmembrane domain. The structure and the chemical characterization of CXCL9, as well as its effects on autoimmune deseases, allograft rejection, cancer therapy were reviewed.